Adagene (ADAG) financial statements

Healthcare · Biotechnology · Market cap $173M

Adagene reported revenue of $8M in fiscal 2025, up 26.1% a year over 7 years.

Net income was -$18M and the operating margin -279.5%, against -1147.1% in 2018.

Free cash flow was -$16M.

The diluted share count rose 289% over the period (dilution).

Revenue and free cash flow

Fiscal years, $ billions.

-0.1-0.0-0.000.020182019202020212022202320242025RevenueFree cash flow
Embed this chart

Free to use in articles and newsletters with the source line. Paste this HTML:

Income statement

Fiscal years, from Adagene's 10-K filings with the SEC.

Fiscal year20182019202020212022202320242025
Revenue$2M$480,000$700,913$10M$9M$18M$103,204$8M
Research and development$16M$16M$34M$68M$81M$37M$29M$22M
Selling, general and admin$3M$3M$10M$14M$12M$9M$7M$7M
Operating income-$17M-$19M-$43M-$72M-$84M-$24M-$36M-$21M
Interest expense$91,085$138,096$202,165$363,762$693,323$1M$851,874$463,132
Pre-tax income-$15M-$16M-$42M-$17M-$13M-$17M-$33M-$18M
Income tax———$2M$459,055$2M-$17,553-$297,860
Net income-$15M-$16M-$42M-$73M-$80M-$19M-$33M-$18M
EPS (diluted)-$0.94-$1.10-$2.67-$1.46-$0.31-$0.35-$0.59-$0.30
Diluted shares15M15M16M50M55M55M56M59M
Operating margin-1147.1%-3993.7%-6156.5%-711.2%-903.1%-131.0%-34835.4%-279.5%
Net margin-1010.2%-3423.4%-6048.9%-719.2%-860.6%-104.6%-32386.4%-229.6%

Balance sheet

Fiscal years, from Adagene's 10-K filings with the SEC.

Fiscal year20182019202020212022202320242025
Cash and short-term investments$16M$101M$75M$174M$144M$110M$85M$75M
Receivables—$480,000—$3M————
Total current assets—$104M$79M$186M$149M$113M$88M$77M
Property, plant and equipment—$2M$2M$3M$3M$2M$1M$717,374
Total assets—$106M$84M$190M$152M$116M$89M$78M
Total current liabilities—$7M$16M$30M$55M$31M$38M$25M
Long-term debt—$2M$3M$3M$14M$14M$417,339$1M
Total liabilities—$9M$19M$33M$69M$45M$39M$26M
Shareholders' equity-$41M-$57M-$89M$157M$83M$71M$51M$35M
Net debt-$16M-$91M-$71M-$170M-$127M-$92M-$72M-$73M

Cash flow

Fiscal years, from Adagene's 10-K filings with the SEC.

Fiscal year20182019202020212022202320242025
Operating cash flow-$14M-$18M-$29M-$43M-$49M-$28M-$30M-$16M
Capital spending$514,703$151,829$935,199$3M$690,938$85,012$33,580$17,053
Free cash flow-$15M-$18M-$29M-$46M-$49M-$29M-$30M-$16M
Stock-based compensation$126,540$611,711$10M$19M$11M$7M$5M$4M
Share buybacks (net)———-$2M-$4M———
Net borrowing$1M$234,682$5M-$702,857$21M-$5M-$3M-$12M
Free cash flow margin-978.0%-3813.6%-4203.8%-451.3%-530.6%-157.6%-28811.4%-204.3%
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ADAG.
Open ADAG in Investingly

Questions

What was Adagene's revenue in 2025?

$8M in fiscal 2025, from its 10-K filing.

How much free cash flow does Adagene generate?

-$16M in fiscal 2025 (operating cash flow minus capital spending).

From Adagene's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.